News
ALT
7.85
+5.02%
0.38
Weekly Report: what happened at ALT last week (0415-0419)?
Weekly Report · 1d ago
13 new obesity drugs could hit the market by 2029 amid surging demand
13 new obesity drugs could hit the market by 2029 amid surging demand for the products in the U.S. World Health Organization predicts 50% of US adults will be considered obese by 2030. Sales of weight-loss drugs have soared, with Novo Nordisk and Eli Lilly generating $9.7B in 2023.
Seeking Alpha · 1d ago
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
Recent trial data from Viking Therapeutics could make it a potential acquisition target for Pfizer. The GLP-1 weight loss market is projected to grow to $100 billion by 2030. Novo Nordisk and Eli Lilly are the leaders in the space. Pfizer makes logical sense in a potential deal for Viking. The company recently completed a successful Phase 2 trial of its drug in the obesity treatment.
Seeking Alpha · 04/15 20:08
Weekly Report: what happened at ALT last week (0408-0412)?
Weekly Report · 04/15 10:37
Buy Altimmune's Potential Market Disruption With Pemvidutide
Altimmune, Inc. Is a clinical-stage biopharmaceutical company focused on developing peptide-based treatments for obesity and liver diseases. Its lead drug candidate, Pemvidutide, has shown promising results in clinical trials for obesity. The drug candidate targets glucagon-like peptide 1 and glucagon receptors to produce weight loss with reduced side effects. ALT is a viable investment for investors who are aware of the risks in biotech.
Seeking Alpha · 04/12 16:02
How Is The Market Feeling About Altimmune?
Altimmune's short percent of float has risen 15.72% since its last report. The company has 12.51 million shares sold short, which is 17.81% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/08 13:00
Weekly Report: what happened at ALT last week (0401-0405)?
Weekly Report · 04/08 10:40
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
3 analysts have maintained Buy ratings on Roivant Sciences, Terns Pharmaceuticals and Altimmune. The Healthcare sector is a hot area for insiders to make moves following their insider activities. The analysts maintain bullish sentiments on all 3 stocks in a report released today. Roivant sciences, terns pharmaceuticals and altimmune are all in the healthcare sector.
TipRanks · 04/03 12:11
U.S. RESEARCH ROUNDUP- Biomea Fusion, BlackRock, Capital Bancorp
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Biomea Fusion, BlackRock, Capital Bancorp and 3M among companies. JP Morgan raises target price to $767 from $742 for BlackRock. 3M Co, Advance Auto Parts and AIG among companies with target price cuts.
Reuters · 04/02 07:59
ALTIMMUNE INC <ALT.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $12 FROM $15
Reuters · 04/02 04:16
Altimmune Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/01 16:33
Altimmune Price Target Cut to $12.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 04/01 16:33
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $12
Benzinga · 04/01 16:23
Altimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
TipRanks · 04/01 16:15
Weekly Report: what happened at ALT last week (0325-0329)?
Weekly Report · 04/01 10:39
Eli Lilly: Three Threats To Its Huge Rally
Drug giant Eli Lilly's stock has surged 130% over the past 12 months. The company's new weight loss products are a huge new market in the pharma market. The stock has a massive $700 billion market cap. The rally has been powered by the success of its new drugs. Three key threats to the rally include increased Congressional scrutiny and competition.
Seeking Alpha · 03/31 14:47
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
NASDAQ · 03/29 16:00
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 03/28 18:08
Altimmune Price Target Maintained With a $20.00/Share by B. Riley Securities
Dow Jones · 03/28 16:06
B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Benzinga · 03/28 15:56
More
Webull provides a variety of real-time ALT stock news. You can receive the latest news about Altimmune through multiple platforms. This information may help you make smarter investment decisions.
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.